查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1593906

溶小体贮积症市场：按疾病类型、治疗类型和最终用户划分 - 全球预测 2025-2030

Lysosomal Storage Diseases Market by Disease Type (Fabry Diseases, Gaucher's Diseases, Mucopolysaccharidosis), Type of Therapy (Enzyme Replacement Therapy, Stem Cell Therapy, Substrate Reduction Therapy), End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年溶小体贮积症市场价值为93.1亿美元，预计到2024年将达到99.8亿美元，复合年增长率为7.48%，到2030年将达到154.3亿美元。

溶小体贮积症（LSD）是一组罕见的代谢性疾病，其特征是酵素缺乏，未消化的大分子在溶小体中积聚。鑑于这些疾病的严重性及其对患者生活品质的影响，迫切需要加强诊断、治疗和治疗提供方法。主要应用是酵素替代疗法（ERT）、基材减少疗法和基因疗法。最终用户范围从专业医疗机构到专门研究罕见疾病的研究机构。市场成长是由人们对罕见疾病的认识不断提高、研究成本不断上升以及基因组研究的进步所推动的。主要影响因素包括生物技术投资的增加以及支持孤儿药开发的有利政府政策框架。利用 CRISPR 和其他基因编辑技术可能会为 LSD开拓新的治疗方法。此外，製药公司和研究机构之间的合作加速了创新。然而，高昂的治疗费用、严格的监管和有限的患者群等限制因素可能会阻碍大规模投资。财务永续性、负担能力和治疗方法的可近性仍然是挑战。药物输送系统的创新以及个人化医疗人工智慧的整合是提高治疗效果和患者预后的有希望的途径。市场洞察表明，对利基技术进步、策略伙伴关係以及研发的投资对于抓住新机会至关重要。儘管市场主要由现有的治疗方法定义，但目前正在转向下一代治疗方法，包括基因治疗和个人化医疗。相关人员应专注于协作方法和以患者为中心的解决方案，以应对这一复杂的情况并实现永续成长。透过促进创新和提高全球意识，该行业可以解决现有的局限性，并推动新兴但不断发展的溶酶体贮积症领域的市场大幅扩张。

主要市场统计
基准年[2023] 93.1亿美元
预测年份 [2024] 99.8亿美元
预测年份 [2030] 154.3亿美元
复合年增长率（%） 7.48%

市场动态：快速发展的溶小体贮积症市场的关键市场洞察

供需的动态交互作用正在改变溶小体贮积症市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 溶小体贮积症的全球盛行率
    • 倾向于疾病的早期诊断和治疗
    • 增加酵素替代疗法的使用
  • 市场限制因素
    • 治疗溶小体贮积症相关的高成本
  • 市场机会
    • 基因编辑技术和基因治疗的进展
    • 治疗溶小体贮积症的个人化医疗方法的出现
  • 市场挑战
    • 溶小体储存药物核准的严格法律规范

波特五力：驾驭溶小体贮积症市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解对溶小体贮积症市场的外部影响

外部宏观环境因素在塑造溶小体贮积症市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解溶小体贮积症市场的竞争状况

溶小体贮积症市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的见解，以应对日益激烈的竞争。

FPNV 定位矩阵溶小体贮积症市场供应商的绩效评估

FPNV 定位矩阵是评估溶小体贮积症市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了溶小体贮积症市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对溶小体贮积症市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告提供了涵盖关键重点领域的市场全面分析：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球溶小体贮积症的盛行率
      • 疾病的早​​期诊断和治疗趋势
      • 增加酵素替代疗法的使用
    • 抑制因素
      • T-溶小体储积症的治疗费用高昂
    • 机会
      • 基因编辑技术和基因治疗的进展
      • 治疗溶小体储积症的个人化医疗方法的出现
    • 任务
      • 溶小体储存药物核准的严格法规结构
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章溶小体贮积症市场：依疾病类型

  • 法布瑞氏症
  • 高雪氏症
  • 黏多醣症
  • 庞贝氏症候群

第七章依治疗类型分類的溶小体贮积症市场

  • 酵素替代疗法
  • 干细胞疗法
  • 基材减少疗法

第八章溶小体贮积症市场：依最终用户分类

  • 诊所
  • 医院

第九章北美及南美溶小体贮积症市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区溶小体贮积症市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲溶小体贮积症市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abeona Therapeutics Inc.
  • Alexion Pharmaceuticals, Inc.
  • Amicus Therapeutics
  • ArmaGen, Inc.
  • BioMarin
  • CHIESI USA, Inc.
  • Denali Therapeutics Inc.
  • Freeline Therapeutics
  • Homology Medicines, Inc.
  • Horizon Pharma PLC
  • Idorsia Pharmaceuticals Ltd.
  • JCR Pharmaceuticals Co., Ltd.
  • Lysogene
  • Neurogene Inc.
  • Novartis AG
  • Orchard Therapeutics Limited
  • Pfizer Inc.
  • Protalix
  • Sangamo Therapeutics, Inc.
  • Sanofi SA
  • Spark Therapeutics, Inc.
  • Swedish Orphan Biovitrum AB
  • Takeda Pharmaceutical Company Limited
  • Ultragenyx Pharmaceutical Inc.
Product Code: MRR-DD0700E81E5B

The Lysosomal Storage Diseases Market was valued at USD 9.31 billion in 2023, expected to reach USD 9.98 billion in 2024, and is projected to grow at a CAGR of 7.48%, to USD 15.43 billion by 2030.

Lysosomal Storage Diseases (LSDs) are a group of rare metabolic disorders characterized by an enzyme deficiency, leading to the accumulation of undigested macromolecules in lysosomes. Given the severe nature of these diseases and their impact on patient quality of life, there is a pressing necessity for enhanced diagnostics, treatments, and therapeutic delivery methods. The primary application revolves around enzyme replacement therapy (ERT), substrate reduction therapy, and gene therapy. End-users range from specialized healthcare facilities to research institutions dedicated to orphan diseases. The market growth is driven by increasing awareness, rising healthcare spending in rare diseases, and advancements in genomic research. Key influencers include growing investments in biotechnology and favorable government policy frameworks supporting orphan drug development. Opportunities lie in leveraging CRISPR and other gene-editing technologies to pioneer novel treatment approaches for LSDs. Additionally, collaborations between pharmaceutical companies and research institutions can accelerate innovation. However, limitations persist due to the high cost of treatment, stringent regulatory barriers, and the limited patient pool, which might deter large-scale investments. Financial sustainability, affordability, and accessibility of therapies remain challenging. Innovating in drug delivery systems and integrating artificial intelligence for personalized medicine are promising avenues to enhance treatment efficacy and patient outcomes. Market insights suggest that niche technological advancements, strategic partnerships, and investment in R&D are critical for capturing emerging opportunities. Although the market is primarily defined by established treatments, there is a pivot towards next-gen therapies involving gene and personalized medicine. Stakeholders should focus on collaborative approaches and patient-centric solutions to navigate the complex landscape, aiming for sustainable growth. By fostering innovation and enhancing global awareness, the industry can address existing limitations and propel significant market expansion in the nascent but evolving field of lysosomal storage diseases.

KEY MARKET STATISTICS
Base Year [2023] USD 9.31 billion
Estimated Year [2024] USD 9.98 billion
Forecast Year [2030] USD 15.43 billion
CAGR (%) 7.48%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Lysosomal Storage Diseases Market

The Lysosomal Storage Diseases Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of lysosomal storage disorders worldwide
    • Inclination toward early diagnosis and treatment of diseases
    • Increasing use of enzyme replacement therapies
  • Market Restraints
    • High cost associated with the treatment of t lysosomal storage disease
  • Market Opportunities
    • Advancements in gene editing technologies and gene therapies
    • Emergence of personalized medicine approach to treat lysosomal storage conditions
  • Market Challenges
    • Stringent regulatory framework for approval of lysosomal storage drugs

Porter's Five Forces: A Strategic Tool for Navigating the Lysosomal Storage Diseases Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Lysosomal Storage Diseases Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Lysosomal Storage Diseases Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Lysosomal Storage Diseases Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Lysosomal Storage Diseases Market

A detailed market share analysis in the Lysosomal Storage Diseases Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Lysosomal Storage Diseases Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Lysosomal Storage Diseases Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Lysosomal Storage Diseases Market

A strategic analysis of the Lysosomal Storage Diseases Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Lysosomal Storage Diseases Market, highlighting leading vendors and their innovative profiles. These include Abeona Therapeutics Inc., Alexion Pharmaceuticals, Inc., Amicus Therapeutics, ArmaGen, Inc., BioMarin, CHIESI USA, Inc., Denali Therapeutics Inc., Freeline Therapeutics, Homology Medicines, Inc., Horizon Pharma PLC, Idorsia Pharmaceuticals Ltd., JCR Pharmaceuticals Co., Ltd., Lysogene, Neurogene Inc., Novartis AG, Orchard Therapeutics Limited, Pfizer Inc., Protalix, Sangamo Therapeutics, Inc., Sanofi S.A., Spark Therapeutics, Inc., Swedish Orphan Biovitrum AB, Takeda Pharmaceutical Company Limited, and Ultragenyx Pharmaceutical Inc..

Market Segmentation & Coverage

This research report categorizes the Lysosomal Storage Diseases Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Disease Type, market is studied across Fabry Diseases, Gaucher's Diseases, Mucopolysaccharidosis, and Pompe's Syndrome.
  • Based on Type of Therapy, market is studied across Enzyme Replacement Therapy, Stem Cell Therapy, and Substrate Reduction Therapy.
  • Based on End User, market is studied across Clinics and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of lysosomal storage disorders worldwide
      • 5.1.1.2. Inclination toward early diagnosis and treatment of diseases
      • 5.1.1.3. Increasing use of enzyme replacement therapies
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with the treatment of t lysosomal storage disease
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in gene editing technologies and gene therapies
      • 5.1.3.2. Emergence of personalized medicine approach to treat lysosomal storage conditions
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory framework for approval of lysosomal storage drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Lysosomal Storage Diseases Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Fabry Diseases
  • 6.3. Gaucher's Diseases
  • 6.4. Mucopolysaccharidosis
  • 6.5. Pompe's Syndrome

7. Lysosomal Storage Diseases Market, by Type of Therapy

  • 7.1. Introduction
  • 7.2. Enzyme Replacement Therapy
  • 7.3. Stem Cell Therapy
  • 7.4. Substrate Reduction Therapy

8. Lysosomal Storage Diseases Market, by End User

  • 8.1. Introduction
  • 8.2. Clinics
  • 8.3. Hospitals

9. Americas Lysosomal Storage Diseases Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Lysosomal Storage Diseases Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Lysosomal Storage Diseases Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abeona Therapeutics Inc.
  • 2. Alexion Pharmaceuticals, Inc.
  • 3. Amicus Therapeutics
  • 4. ArmaGen, Inc.
  • 5. BioMarin
  • 6. CHIESI USA, Inc.
  • 7. Denali Therapeutics Inc.
  • 8. Freeline Therapeutics
  • 9. Homology Medicines, Inc.
  • 10. Horizon Pharma PLC
  • 11. Idorsia Pharmaceuticals Ltd.
  • 12. JCR Pharmaceuticals Co., Ltd.
  • 13. Lysogene
  • 14. Neurogene Inc.
  • 15. Novartis AG
  • 16. Orchard Therapeutics Limited
  • 17. Pfizer Inc.
  • 18. Protalix
  • 19. Sangamo Therapeutics, Inc.
  • 20. Sanofi S.A.
  • 21. Spark Therapeutics, Inc.
  • 22. Swedish Orphan Biovitrum AB
  • 23. Takeda Pharmaceutical Company Limited
  • 24. Ultragenyx Pharmaceutical Inc.

LIST OF FIGURES

  • FIGURE 1. LYSOSOMAL STORAGE DISEASES MARKET RESEARCH PROCESS
  • FIGURE 2. LYSOSOMAL STORAGE DISEASES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. LYSOSOMAL STORAGE DISEASES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. LYSOSOMAL STORAGE DISEASES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. LYSOSOMAL STORAGE DISEASES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. LYSOSOMAL STORAGE DISEASES MARKET DYNAMICS
  • TABLE 7. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY FABRY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY GAUCHER'S DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY MUCOPOLYSACCHARIDOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY POMPE'S SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 146. LYSOSOMAL STORAGE DISEASES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. LYSOSOMAL STORAGE DISEASES MARKET, FPNV POSITIONING MATRIX, 2023